Filing Analysis
💸 Securities Offering
Filed Jun 11, 2026
🟠 HIGH
Palisade Bio held its 2026 Annual Meeting of Stockholders on June 10, 2026, resulting in a significant increase in authorized common stock and the appointment of a new director. The company also approved amended equity incentive and employee stock purchase plans.
🚩 Red Flags
- Significant increase in authorized shares (50% increase from 300M to 450M), which typically signals potential future dilution for existing shareholders.
- Multiple 8-K items (5.02, 5.03, 5.07) reported in a single filing.
- High equity grant ($566,000) for a new non-employee director relative to typical micro-cap compensation.
📋 Key Facts
- Authorized common stock increased from 300,000,000 to 450,000,000 shares, effective June 11, 2026.
- Jordan Zwick was appointed to the Board of Directors and the Audit Committee, receiving an initial RSU grant valued at $566,000 vesting over three years.
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan and the Amended and Restated 2021 Employee Stock Purchase Plan.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Four directors were elected: J.D. Finley, Donald Williams, Emil Chuang, and Robert F. Baltera, Jr.
📢 Regulation FD Disclosure
Filed May 12, 2026
⚪ LOW
Palisade Bio, Inc. announced its financial results for the first fiscal quarter ended March 31, 2026. The announcement was made via a press release and filed under Item 2.02 of Form 8-K.
📋 Key Facts
- The report covers the three months ended March 31, 2026.
- The filing was made on May 12, 2026, the same day as the press release.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- J.D. Finley, Chief Executive Officer, signed the report.
💸 Securities Offering
Filed Apr 02, 2026
🟡 MEDIUM
Palisade Bio entered into a strategic partnership with Iterative Health to expedite Phase 2 clinical trial enrollment for PALI-2108 and simultaneously secured a $3.0 million private placement investment from an affiliate of the partner.
🚩 Red Flags
- The transaction involves a private placement (PIPE), which results in immediate dilution of existing shareholders.
📋 Key Facts
- Entered into a Master Services Agreement (MSA) with Iterative Scopes, Inc. (d/b/a Iterative Health) on March 30, 2026.
- The MSA is designed to assist with Study Enrollment for a Phase 2 study of PALI-2108 for moderate to severe Ulcerative Colitis.
- Issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health on March 27, 2026.
- The total purchase price was $3.0 million, representing $1.952 per share.
- The share price was calculated based on the average closing price for the five trading days prior to the Closing Date.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.